Displaying 14 results of Ertugliflozin Impurities Ertugliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor used to treat type 2 diabetes. The drug may contain impurities that can affect its safety and efficacy. The most common impurities include related compounds, process impurities, and residual solvents. The presence of these impurities can impact the quality, purity, and stability of the drug product, and may pose a risk to patient safety. Therefore, it is important to